STING Agonists as Cancer Therapeutics.
Amouzegar A, Chelvanambi M, Filderman JN, Storkus WJ, Luke JJ. · 2021
Read STING Agonists as Cancer Therapeutics. by Amouzegar A, Chelvanambi M, Filderman JN, Storkus WJ, Luke JJ. (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc8198217.txt.
Description
Amouzegar and co-authors assess STING agonists as cancer therapeutics. Many patients still fail to respond to immunotherapy. STING, a protein in the cell, triggers type I interferons and other alarm signals.
Natural and synthetic agonists have been tested in lab and clinic. Early compounds broke down too fast to work well. Newer classes are more stable and more potent. The review sorts these drug classes and their trial record. It weighs which tumours suit this route. STING offers a way to wake the immune system inside a tumour. Both pre-clinical and clinical test settings are covered.
Catalog record
| CREATOR | Amouzegar A, Chelvanambi M, Filderman JN, Storkus WJ, Luke JJ. |
|---|---|
| YEAR | 2021 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 75 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |